drugset / Trial / NCT00004981

Safety and Effectiveness of Three Anti-HIV Drugs Combined in One Pill (Trizivir)

NCT00004981

Phase 3 Unknown 230 enrolled Glaxo Wellcome
Treatment

Summary

The purpose of this study is to look at the safety and effectiveness of a pill called Trizivir that is a combination of three anti-HIV drugs (zidovudine, lamivudine, and abacavir). Zidovudine and lamivudine are often given combined in one pill (Combivir). In this study, Trizivir will be compared to Combivir plus abacavir.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Background Abacavir Other / unclassified 300 mg
Background Lamivudine Other / unclassified 150 mg Oral
Background Zidovudine Small molecule 300 mg Oral